Literature DB >> 1425809

In vitro forecasting of drugs that may interfere with codeine bioactivation.

P Dayer1, J Desmeules, R Striberni.   

Abstract

The O-demethylation of codeine (methylmorphine) into morphine is mediated by the polymorphic cytochrome P450 DB1 (P450 IID6). By means of in vitro screening in human liver microsomes we have studied the effect on codeine bioactivation of several drugs used as analgesics or as adjuvants for pain control. In microsomes from an extensive metabolizer subject, paracetamol (acetaminophen) and NSAIDs (acetylsalicylic acid, diclofenac, indomethacin, piroxicam, and pirprofen), benzodiazepines (chlordiazepoxide, clonazepam, diazepam, flunitrazepam, and midazolam), and anticonvulsants (carbamazepine and phenytoin) did not alter the reaction. There was marked inhibition of in vitro morphine production by neuroleptics (chlorpromazine, haloperidol, levomepromazine, and thioridazine), metoclopramide, and tricyclic antidepressants (amitriptyline, clomipramine, desipramine, imipramine, and nortriptyline). Enzyme kinetics showed competitive inhibition by neuroleptics (chlorpromazine Ki = 0.5 microM) and antidepressants (clomipramine Ki = 6.8 microM), which are substrates of the polymorphic monooxygenase. Due to the low affinity of codeine for P450 DB1 (Km = 100-200 microM), its bioactivation in extensive metabolizers, and thus its analgesic efficacy, is liable to vary greatly when it is combined with any drug that has a high affinity for the polymorphic isozyme.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1425809     DOI: 10.1007/BF03188779

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  21 in total

1.  The determination of enzyme inhibitor constants.

Authors:  M DIXON
Journal:  Biochem J       Date:  1953-08       Impact factor: 3.857

Review 2.  The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects.

Authors:  M Eichelbaum; A S Gross
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

3.  Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450 db1 activity.

Authors:  P Dayer; T Leemann; R Striberni
Journal:  Clin Pharmacol Ther       Date:  1989-01       Impact factor: 6.875

4.  A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man.

Authors:  M D Nielsen; K Brøsen; L F Gram
Journal:  Br J Clin Pharmacol       Date:  1990-03       Impact factor: 4.335

5.  Polymorphic O-demethylation of codeine.

Authors:  Z R Chen; A A Somogyi; F Bochner
Journal:  Lancet       Date:  1988-10-15       Impact factor: 79.321

6.  Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI).

Authors:  P Dayer; J Desmeules; T Leemann; R Striberni
Journal:  Biochem Biophys Res Commun       Date:  1988-04-15       Impact factor: 3.575

7.  Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase.

Authors:  F J Gonzalez; B J Schmid; M Umeno; O W Mcbride; J P Hardwick; U A Meyer; H V Gelboin; J R Idle
Journal:  DNA       Date:  1988-03

8.  Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites.

Authors:  A E Balant-Gorgia; L P Balant; C Genet; P Dayer; J M Aeschlimann; G Garrone
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

9.  The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.

Authors:  U A Meyer; J Gut; T Kronbach; C Skoda; U T Meier; T Catin; P Dayer
Journal:  Xenobiotica       Date:  1986-05       Impact factor: 1.908

10.  Characterization of the common genetic defect in humans deficient in debrisoquine metabolism.

Authors:  F J Gonzalez; R C Skoda; S Kimura; M Umeno; U M Zanger; D W Nebert; H V Gelboin; J P Hardwick; U A Meyer
Journal:  Nature       Date:  1988-02-04       Impact factor: 49.962

View more
  5 in total

Review 1.  Pharmacokinetics of haloperidol: an update.

Authors:  S Kudo; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

Review 2.  Pharmacokinetic changes in the elderly. Do they contribute to drug abuse and dependence?

Authors:  V Ozdemir; J Fourie; U Busto; C A Naranjo
Journal:  Clin Pharmacokinet       Date:  1996-11       Impact factor: 6.447

Review 3.  Rational prescription of drugs within similar therapeutic or structural class for gastrointestinal disease treatment: drug metabolism and its related interactions.

Authors:  Quan Zhou; Xiao-Feng Yan; Zhong-Miao Zhang; Wen-Sheng Pan; Su Zeng
Journal:  World J Gastroenterol       Date:  2007-11-14       Impact factor: 5.742

4.  O-demethylation of codeine to morphine inhibited by low-dose levomepromazine.

Authors:  M Vevelstad; S Pettersen; C Tallaksen; O Brørs
Journal:  Eur J Clin Pharmacol       Date:  2009-03-24       Impact factor: 2.953

5.  Diclofenac does not interact with codeine metabolism in vivo: a study in healthy volunteers.

Authors:  Susanne Ammon; Claudia Marx; Christoph Behrens; Ute Hofmann; Thomas Mürdter; Ernst-Ulrich Griese; Gerd Mikus
Journal:  BMC Clin Pharmacol       Date:  2002-02-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.